AR035804A1 - NOVELTY INHIBITORS OF TYROSINE KINASE - Google Patents

NOVELTY INHIBITORS OF TYROSINE KINASE

Info

Publication number
AR035804A1
AR035804A1 ARP020101167A ARP020101167A AR035804A1 AR 035804 A1 AR035804 A1 AR 035804A1 AR P020101167 A ARP020101167 A AR P020101167A AR P020101167 A ARP020101167 A AR P020101167A AR 035804 A1 AR035804 A1 AR 035804A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
heteroaryl
alkenyl
aryl
Prior art date
Application number
ARP020101167A
Other languages
Spanish (es)
Inventor
Mark D Wittman
Neelakantan Balasubramanian
Upender Velaparthi
Kurt Zimmermann
Mark G Saulnier
Peiying Liu
Xiaopeng Sang
David B Frennesson
Karen M Stoffan
James G Tarrant
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR035804A1 publication Critical patent/AR035804A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Un compuesto de conformidad con la fórmula (1), sus enantiómeros, diastereómeros, sales farmacéuticamente aceptables, hidratos, profármacos y solvatos de los mismos; en donde X se selecciona del grupo que consiste de N, C, alquilo C1-3, alquilo C1-3 sustituido con uno o más de R7, y un enlace directo; Y se selecciona del grupo que consiste de O y S; W se selecciona del grupo que consiste de N, C, O, y S, con la condición de que cuando W es O o S, R9 está ausente; R1, R2, R3, R4, R5, R6, R7, R8, R9 cada uno se seleccionan independientemente del grupo que consiste de H, alquilo C1-6, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, halo, amino, OR60, NO2, OH, SR60, NR60R61, CN, CO2R60, CONR60R61, OCONR60R61, NR62CONR60R61, NR60SO2R61, SO2NR60R61, C(NR62)NR60R61, arilo, heteroarilo, (CH2)nOR60, (CH2)nNR60R61, (CH2)nSR60, (CH2)n arilo, (CH2)nheteroarilo, (CH2)nheterocicloalquilo, NH-Z-arilo, y NH-Z-heteroarilo; en donde n es 1 hasta 3; y Z se selecciona del grupo que consiste de cadena alquilo C1-4, alquenilo, y alquinilo; Z tiene uno o más grupos, hidroxi, tiol, alcoxi, tioalcoxi, amino, halo, NR60SO2R61; Z incorpora opcionalmente uno o más grupos seleccionados del grupo que consiste de CO, CNOH, CNOR60, CNNR60, CNNCOR60 y CNNSO2R60; y R60 y R61 se seleccionan independientemente del grupo que consiste de H, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, hidroxi, alcoxi, arilo, heteroarilo, heteroarilalquilo y alquilo -R25 en donde R25 es hidrógeno, alquenilo, hidroxi, tiol, alcoxi, tioalcoxi, amino, alquilamino, dialquilamino, arilo, heteroarilo, ciano, halo, sulfoxi, sulfonilo, NR30COOR31, -NR30C(O)R31, -NR30SO2R31, C(O)NR30R31, heteroarilo o heterocicloalquilo; y R30 y R31 son, independientemente, hidrógeno, alquilo, cicloalquilo, o alquilo-R25. Composiciones farmacéuticas que comprenden un compuesto de fórmula (1) y un portador farmacéuticamente aceptable. Los compuestos de fórmula (1) inhiben las enzimas de la tirosina quinasa y son útiles para el tratamiento de enfermedades que se caracterizan por una sobre-expresión o sobre-regulación de la actividad de la tirosina cinasa, tales como cáncer, diabetes, restenosis, arteriosclerosis, psoriasis, enfermedades angiogénicas y desórdenes inmunogénicos.A compound according to formula (1), its enantiomers, diastereomers, pharmaceutically acceptable salts, hydrates, prodrugs and solvates thereof; wherein X is selected from the group consisting of N, C, C1-3 alkyl, C1-3 alkyl substituted with one or more of R7, and a direct bond; And it is selected from the group consisting of O and S; W is selected from the group consisting of N, C, O, and S, with the proviso that when W is O or S, R9 is absent; R1, R2, R3, R4, R5, R6, R7, R8, R9 are each independently selected from the group consisting of H, C1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, OR60, NO2, OH, SR60, NR60R61, CN, CO2R60, CONR60R61, OCONR60R61, NR62CONR60R61, NR60SO2R61, SO2NR60R61, C (NR62) NR60R61, aryl, heteroaryl, (CH2) nOR60, (CH2) nNR60R61, (CH2) nSR60, CH2) nSR60, CH2) nSR60, CH2) , (CH2) nheteroaryl, (CH2) nheterocycloalkyl, NH-Z-aryl, and NH-Z-heteroaryl; where n is 1 to 3; and Z is selected from the group consisting of C1-4 alkyl chain, alkenyl, and alkynyl; Z has one or more groups, hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, NR60SO2R61; Z optionally incorporates one or more groups selected from the group consisting of CO, CNOH, CNOR60, CNNR60, CNNCOR60 and CNNSO2R60; and R60 and R61 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl and alkyl -R25 wherein R25 is hydrogen, alkenyl, hydroxy, thiol, alkoxy , thioalkoxy, amino, alkylamino, dialkylamino, aryl, heteroaryl, cyano, halo, sulfoxy, sulfonyl, NR30COOR31, -NR30C (O) R31, -NR30SO2R31, C (O) NR30R31, heteroaryl or heterocycloalkyl; and R30 and R31 are independently hydrogen, alkyl, cycloalkyl, or alkyl-R25. Pharmaceutical compositions comprising a compound of formula (1) and a pharmaceutically acceptable carrier. The compounds of formula (1) inhibit tyrosine kinase enzymes and are useful for the treatment of diseases characterized by an over-expression or over-regulation of tyrosine kinase activity, such as cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases and immunogenic disorders.

ARP020101167A 2001-03-28 2002-03-27 NOVELTY INHIBITORS OF TYROSINE KINASE AR035804A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28

Publications (1)

Publication Number Publication Date
AR035804A1 true AR035804A1 (en) 2004-07-14

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101167A AR035804A1 (en) 2001-03-28 2002-03-27 NOVELTY INHIBITORS OF TYROSINE KINASE

Country Status (25)

Country Link
EP (1) EP1381598A4 (en)
JP (1) JP2004534010A (en)
KR (1) KR20030083016A (en)
CN (1) CN1514833A (en)
AR (1) AR035804A1 (en)
BG (1) BG108206A (en)
BR (1) BR0208373A (en)
CA (1) CA2442428A1 (en)
CZ (1) CZ20032615A3 (en)
EE (1) EE200300475A (en)
GE (1) GEP20053660B (en)
HR (1) HRP20030844A2 (en)
HU (1) HUP0400323A2 (en)
IL (1) IL158041A0 (en)
IS (1) IS6968A (en)
MX (1) MXPA03008690A (en)
NO (1) NO20034308L (en)
PE (1) PE20021015A1 (en)
PL (1) PL373300A1 (en)
RU (1) RU2003131693A (en)
SK (1) SK12002003A3 (en)
UY (1) UY27234A1 (en)
WO (1) WO2002079192A1 (en)
YU (1) YU84603A (en)
ZA (1) ZA200307466B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US7265260B2 (en) 2002-03-01 2007-09-04 Bristol-Myers Squibb Company Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
JP2005532368A (en) * 2002-06-12 2005-10-27 アボット・ラボラトリーズ Melanin-concentrating hormone receptor antagonist
US7361691B2 (en) * 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
WO2004063151A2 (en) * 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
WO2004069160A2 (en) * 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
DE102004010207A1 (en) 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
US7534797B2 (en) 2004-04-02 2009-05-19 Osi Pharmaceuticals, Inc. 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
MX2007007330A (en) * 2004-12-16 2007-10-04 Vertex Pharma Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
WO2006130657A2 (en) 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1909910A1 (en) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006284900A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
JP2009507792A (en) * 2005-08-29 2009-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド 3,5-Disubstituted pyrid-2-ones useful as inhibitors of the TEC family of non-receptor tyrosine kinases
EP1919905B1 (en) 2005-08-29 2011-02-23 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases
WO2007026720A1 (en) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Ring-fused pyrazole derivative
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (en) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. Optically active 2-amino-1-(4-fluorophenyl)ethanol
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US7956190B2 (en) 2007-06-25 2011-06-07 Hoffmann-La Roche Inc. Benzimidazole amido derivatives as kinase inhibitors
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CN101970424B (en) 2008-01-22 2013-06-12 弗奈利斯（R&D）有限公司 Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity
WO2009143051A1 (en) 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Substituted imidazopyr-and imidazotri-azines
PE20120057A1 (en) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc SIRTUINE MODULATING THIAZOLOPYRIDINE COMPOUNDS
DE102010001064A1 (en) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
MX2011011025A (en) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparation of c-pyrazine-methylamines.
EP2435435B1 (en) * 2009-05-27 2014-01-29 AbbVie Inc. Pyrimidine inhibitors of kinase activity
EP2494070A2 (en) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
PL2624696T3 (en) * 2010-10-06 2017-07-31 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP5789888B2 (en) * 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazole inhibitors of leukotriene formation
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
JP6599852B2 (en) 2013-06-21 2019-10-30 ゼニス・エピジェネティクス・リミテッド Novel substituted bicyclic compounds as bromodomain inhibitors
BR112015031073B1 (en) 2013-06-21 2022-11-29 Zenith Epigenetics Ltd BICYCLIC BROMODIMANIUM INHIBITORS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS
EA201690087A1 (en) 2013-07-31 2016-08-31 Зенит Эпидженетикс Корп. NEW QUINAZOLINONS AS BROMOMODENIAL INHIBITORS
CN103936719A (en) * 2014-05-14 2014-07-23 中国药科大学 Preparation method and application of benzimidazoles derivatives
CN108064274A (en) 2014-07-30 2018-05-22 耶达研究及发展有限公司 For cultivating the culture medium of multipotential stem cell
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
JP2017537946A (en) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Substituted heterocycles as bromodomain inhibitors
CN107406438B (en) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 Inhibitors of bromodomains
JP6827954B2 (en) * 2015-04-16 2021-02-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 3- (1H-benzimidazol-2-yl) -1H-pyridin-2-one derivative
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2261248C2 (en) * 1999-06-23 2005-09-27 Авентис Фарма Дойчланд Гмбх Substituted benzimidazoles and medicinal agent based on thereof
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
BR0208373A (en) 2005-02-22
GEP20053660B (en) 2005-11-10
EP1381598A1 (en) 2004-01-21
PL373300A1 (en) 2005-08-22
EP1381598A4 (en) 2008-03-19
ZA200307466B (en) 2005-01-13
UY27234A1 (en) 2002-10-31
BG108206A (en) 2004-11-30
EE200300475A (en) 2004-02-16
IS6968A (en) 2003-09-26
NO20034308D0 (en) 2003-09-26
WO2002079192A1 (en) 2002-10-10
KR20030083016A (en) 2003-10-23
CZ20032615A3 (en) 2004-03-17
JP2004534010A (en) 2004-11-11
PE20021015A1 (en) 2002-11-10
IL158041A0 (en) 2004-03-28
HUP0400323A2 (en) 2005-11-28
CN1514833A (en) 2004-07-21
HRP20030844A2 (en) 2005-08-31
MXPA03008690A (en) 2003-12-12
CA2442428A1 (en) 2002-10-10
RU2003131693A (en) 2005-05-10
NO20034308L (en) 2003-11-26
YU84603A (en) 2006-03-03
SK12002003A3 (en) 2004-10-05

Similar Documents

Publication Publication Date Title
AR035804A1 (en) NOVELTY INHIBITORS OF TYROSINE KINASE
CO5560573A2 (en) ACTIVE DERIVATIVES OF AMINO-FTALAZINONA AS QUINASE INHIBITORS, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR035557A1 (en) A METHOD FOR THE TREATMENT OF PROLIFERATIVE DISORDERS OF THE CELLS ASSOCIATED WITH AN ALTERED ACTIVITY OF THE CINASE DEPENDING ON THE CELLS, A DERIVATIVE OF 3-UREIDO-PIRAZOL, A PROCEDURE FOR THE PREPARATION AND A PHARMACEUTICAL COMPOSITION THAT I UNDERSTAND
AR033379A1 (en) DIFENILUREA COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR036659A1 (en) COMPOUNDS DERIVED FROM PHENYL-PIPERAZINE, PHENYL-PIPERIDINE AND PHENYL-TETRAHIDROPIRIDINE AS INHIBITORS OF THE REABSORTION OF SEROTONINE, A PHARMACEUTICAL COMPOSITION AND USE OF THE SAME FOR THE PREPARATION OF MEDICINES
AR021434A1 (en) BENZAMIDA THERAPEUTIC DERIVATIVES
AR034268A1 (en) COMPOUNDS DERIVED FROM PIPERIDINE, ITS USE IN PREPARATION OF MEDICINES, PHARMACEUTICAL COMPOSITION, TREATMENT METHOD AND PROCESS FOR PREPARATION
AR037368A1 (en) IMIDAZOLILPIRROLOTRIAZINAS C-5 MODIFIED AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM
ECSP045229A (en) PIRIDINONES REPLACED AS MODULATORS OF THE P38 MAP QUINASA
RS52978B (en) Fused amino pyridine as hsp90 inhibitors
ES2190396T3 (en) NEW AMINO-TRIAZOL COMPOUNDS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
UY24880A1 (en) ARILSULFONIL HYDROXAMIC ACID DERIVATIVES
NO20054880L (en) Azaspiralane derivatives as inhibitors of metal processes
RU2010149496A (en) Phenoxypyridinilamide derivatives and their use in the treatment of PDE4-mediated disease states
RU2005113153A (en) NEW PYRIMIDINAMIDE DERIVATIVES AND THEIR APPLICATION
AR044177A1 (en) PROCESS FOR THE PREPARATION OF TRANS-ISOMEROS OF DERIVATIVES OF DIFENILAZETIDINONA
AR054102A1 (en) DERIVATIVES OF FENIL-PIPERAZINA-METANONA. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
AR034585A1 (en) NEW SUBSTITUTED CYAN DIHYDROPIRIMIDINE COMPOUNDS AND THEIR USE FOR TREATMENT OF MATTERS
AR041882A1 (en) IMIDAZOPIRIDINE COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TW200616997A (en) The preparation method for 6-substituted-1-methyl-1h-benzoimidazol derivatives and their preparation imtermediates
AR054072A1 (en) 3-AMINO ARILPROPIL INDOLES AS MONOAMINE REABSORTION INHIBITORS. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
AR045091A1 (en) USEFUL NICOTINAMIDE DERIVATIVES AS PDE4 INHIBITORS
CO5590934A2 (en) EQUINOCANDINA DERIVATIVES PREPARATION PROCEDURE
ATE509905T1 (en) BENZAMIDE DERIVATIVES
AR038988A1 (en) COMPOUNDS DERIVED FROM QUINAZOLINA, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
FA Abandonment or withdrawal